• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化伴腹水患者症状负担的生理决定因素。

The physiological determinants of symptom burden in cirrhosis with ascites.

机构信息

Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.

Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.

出版信息

United European Gastroenterol J. 2024 Nov;12(9):1222-1229. doi: 10.1002/ueg2.12675. Epub 2024 Oct 8.

DOI:10.1002/ueg2.12675
PMID:39377420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11578835/
Abstract

BACKGROUND & AIMS: Paracentesis is commonly used to manage patient discomfort due to ascites. The relationship between ascites pressure, ascites volume, and patient discomfort has not been elucidated.

METHODS

We prospectively enrolled adult patients with non-malignant ascites undergoing outpatient therapeutic paracenteses from 2021 to 2024 at a tertiary care hospital. Patients completed a validated symptom questionnaire (ASI-7, maximum score 35) before, immediately after, and 1 week after paracentesis. An open-ended manometer was used to measure ascites pressure at the beginning and end of paracentesis. Mixed effect linear regression was performed to evaluate the relationships between patient characteristics, pressure, volume, and symptoms.

RESULTS

One hundred and fifty paracentesis procedures among 48 unique patients with an average Model for End Stage Liver Disease-Sodium 3.0 of 16.7 were included. An average of 6.5 L was drained, which reduced abdominal pressure from a mean of 13.7 to 6.0 cm HO (10.1 to 4.4 mmHg, p < 0.001) and mean symptom score from 22.6 to 6.5 (p < 0.001). Regression models identified that symptoms and abdominal pressure linearly correlated above a pressure of 6 cm HO or ASI-7 score of 16 (p < 0.01). Taller patients required about 670 ml additional drainage per inch above the cohort mean height (5'8″) to achieve the same symptom relief.

CONCLUSIONS

Pressure measured at the bedside can be used to explore changes in abdominal pressure during paracentesis. Pressure, volume, and patient level factors such as height contribute to patient symptoms but cannot fully explain discomfort associated with ascites and relief after paracentesis.

摘要

背景与目的

腹腔穿刺术常用于缓解腹水引起的患者不适。目前尚未阐明腹水压力、腹水容量与患者不适之间的关系。

方法

我们前瞻性地招募了 2021 年至 2024 年在一家三级保健医院接受门诊治疗性腹腔穿刺术的非恶性腹水成年患者。患者在腹腔穿刺术前、术后即刻和术后 1 周完成了经过验证的症状问卷(ASI-7,最高得分为 35 分)。在腹腔穿刺术开始和结束时,使用开放式压力计测量腹水压力。采用混合效应线性回归评估患者特征、压力、容量和症状之间的关系。

结果

纳入了 48 例患者的 150 次腹腔穿刺术,平均终末期肝病模型钠评分 3.0 为 16.7。平均引流 6.5 L,使腹部压力从平均 13.7 cm HO 降至 6.0 cm HO(10.1 至 4.4 mmHg,p < 0.001),平均症状评分从 22.6 降至 6.5(p < 0.001)。回归模型确定,症状和腹部压力在压力超过 6 cm HO 或 ASI-7 评分超过 16 时呈线性相关(p < 0.01)。比队列平均身高(5'8″)高的患者,每增加 1 英寸需要额外引流约 670 ml 才能达到相同的症状缓解效果。

结论

床边测量的压力可用于探讨腹腔穿刺术期间腹部压力的变化。压力、容量以及患者身高等因素会影响患者症状,但不能完全解释与腹水相关的不适以及腹腔穿刺术后的缓解情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/873567b4c38c/UEG2-12-1222-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/20250cfaa065/UEG2-12-1222-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/7c3e5e644f09/UEG2-12-1222-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/873567b4c38c/UEG2-12-1222-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/20250cfaa065/UEG2-12-1222-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/7c3e5e644f09/UEG2-12-1222-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14fc/11578835/873567b4c38c/UEG2-12-1222-g002.jpg

相似文献

1
The physiological determinants of symptom burden in cirrhosis with ascites.肝硬化伴腹水患者症状负担的生理决定因素。
United European Gastroenterol J. 2024 Nov;12(9):1222-1229. doi: 10.1002/ueg2.12675. Epub 2024 Oct 8.
2
Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.肝硬化腹水症状评估患者报告结局测量工具的开发与验证。
Am J Gastroenterol. 2018 Apr;113(4):567-575. doi: 10.1038/ajg.2018.18. Epub 2018 Mar 20.
3
RESPIRATORY AND SYMPTOMATIC IMPACT OF ASCITES RELIEF BY PARACENTESIS IN PATIENTS WITH HEPATIC CIRRHOSIS.腹腔穿刺放液对肝硬化患者腹水消除的呼吸及症状影响
Arq Gastroenterol. 2020 Jan-Mar;57(1):64-68. doi: 10.1590/S0004-2803.202000000-11.
4
MELD score and albumin replacement are related to higher costs during management of patients with refractory ascites.终末期肝病模型(MELD)评分和白蛋白替代治疗与难治性腹水患者管理期间的较高费用相关。
Transplant Proc. 2014 Jul-Aug;46(6):1760-3. doi: 10.1016/j.transproceed.2014.05.017.
5
Continuous passive paracentesis versus large-volume paracentesis in the prevention and treatment of intra-abdominal hypertension in the critically ill cirrhotic patient with ascites (COPPTRIAHL): study protocol for a randomized controlled trial.连续被动腹腔穿刺术与大量腹腔穿刺术在预防和治疗肝硬化腹水危重症患者腹腔内高压中的应用(COPPTRIAHL):一项随机对照试验的研究方案。
Trials. 2023 Aug 15;24(1):534. doi: 10.1186/s13063-023-07541-4.
6
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.白蛋白可能预防肝硬化和顽固性腹水患者腹腔穿刺术诱发的循环功能障碍的发病:一项初步研究。
Dig Dis Sci. 2016 Oct;61(10):3084-3092. doi: 10.1007/s10620-016-4140-3. Epub 2016 Apr 5.
7
Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis.随机临床试验:姑息性长期腹腔引流与大容量腹腔穿刺放液治疗肝硬化难治性腹水的比较。
Aliment Pharmacol Ther. 2020 Jul;52(1):107-122. doi: 10.1111/apt.15802. Epub 2020 Jun 1.
8
Palliative long-term abdominal drains in refractory ascites due to end-stage liver disease: A case series.终末期肝病所致顽固性腹水的姑息性长期腹腔引流:病例系列
Palliat Med. 2017 Jul;31(7):671-675. doi: 10.1177/0269216316671281. Epub 2016 Oct 5.
9
Central venous pressure catheter for large-volume paracentesis in refractory ascites.用于难治性腹水大量腹腔穿刺术的中心静脉压导管
Indian J Gastroenterol. 2014 Jul;33(4):310-5. doi: 10.1007/s12664-014-0448-0. Epub 2014 Apr 24.
10
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.β受体阻滞剂可引起肝硬化伴难治性腹水患者经皮穿刺放液后循环功能障碍:一项交叉研究。
J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24.

引用本文的文献

1
Response to "Reflections on the Study of Physiological Determinants in Cirrhosis With Ascites".对《关于肝硬化腹水生理决定因素研究的思考》的回应
United European Gastroenterol J. 2025 Mar;13(2):282-283. doi: 10.1002/ueg2.12748. Epub 2024 Dec 26.
2
Reflections on the Study of Physiological Determinants in Cirrhosis With Ascites.肝硬化腹水生理决定因素研究的思考
United European Gastroenterol J. 2025 Mar;13(2):284-285. doi: 10.1002/ueg2.12747. Epub 2024 Dec 23.

本文引用的文献

1
Contemporary management of pain in cirrhosis: Toward precision therapy for pain.肝硬化疼痛的当代管理:走向疼痛精准治疗。
Hepatology. 2023 Jan 1;77(1):290-304. doi: 10.1002/hep.32598. Epub 2022 Jul 6.
2
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.美国老年人群基于人群队列的腹水发生率、风险因素及预后。
Dig Dis Sci. 2022 Nov;67(11):5327-5335. doi: 10.1007/s10620-022-07454-3. Epub 2022 Mar 9.
3
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
腹水、自发性细菌性腹膜炎和肝肾综合征的诊断、评估及管理:美国肝病研究协会2021年实践指南
Hepatology. 2021 Aug;74(2):1014-1048. doi: 10.1002/hep.31884.
4
Optimal Paracentesis Volume for Terminally Ill Cancer Patients With Ascites.终末期癌症合并腹水患者行腹腔穿刺术时的最佳抽液量。
J Pain Symptom Manage. 2021 Nov;62(5):968-977. doi: 10.1016/j.jpainsymman.2021.04.010. Epub 2021 Apr 29.
5
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.欧洲肝脏研究学会失代偿期肝硬化患者管理临床实践指南
J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
6
Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.肝硬化腹水症状评估患者报告结局测量工具的开发与验证。
Am J Gastroenterol. 2018 Apr;113(4):567-575. doi: 10.1038/ajg.2018.18. Epub 2018 Mar 20.
7
Patient-reported outcomes in cirrhosis: A scoping review of the literature.肝硬化患者报告结局的文献计量学分析。
Hepatology. 2018 Jun;67(6):2375-2383. doi: 10.1002/hep.29756. Epub 2018 Apr 19.
8
Development and Validation of a Symptom Scale Specific for Ascites Accompanied with Cirrhosis: The ASI-7.腹水伴肝硬化症状量表的开发与验证:ASI-7。
Clin Transl Gastroenterol. 2014 Feb 6;5(2):e48. doi: 10.1038/ctg.2013.20.
9
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.肝硬化患者生存的自然史及预后指标:118项研究的系统评价
J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013. Epub 2005 Nov 9.
10
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.肝硬化患者治疗性腹腔穿刺放液联合与不联合静脉输注白蛋白的随机对照研究
Gastroenterology. 1988 Jun;94(6):1493-502. doi: 10.1016/0016-5085(88)90691-9.